INTRODUCTION {#s1}
============

Obesity in humans is well acknowledged as the most important, independent risk factor for hypertension \[[@R1]\]. Speaking in general terms, obesity is the amassment of excessive fat in adipose tissue \[[@R2]\]. One of the principal components in adipose tissue is β3-adrenoreceptor, which is abundantly expressed in brown adipose tissue, as well as in subcutaneous and abnormal white adipose tissue \[[@R3], [@R4]\]. An important biological property of β3-adrenoreceptor is to mediate the catecholamine-induced thermogenesis and lipolysis in adipose tissue \[[@R5], [@R6]\]. Another important property involves the enhanced function of sympathetic nervous system, which represents a chief regulator of blood pressure via altering sodium homeostasis and vascular resistance \[[@R7], [@R8]\]. Echoing from this interlocked relation, it is intriguing to speculate that high expression of β3-adrenoreceptor in adipose tissue would lead to elevated blood pressure and ultimately to the great risk of hypertension.

There is evidence that β3-adrenoreceptor expression is partly under genetic control \[[@R9]\]. The extensively-assessed bi-allelic polymorphism in the gene encoding for β3-adrenoreceptor (*ADRB3*, on chromosome 8p11.23) is rs4994, a missense mutation in the 64th position that substitutes a tryptophan with an arginine, termed as Trp64Arg. This substitution can alter the affinity of β3-adrenoreceptor to norepinephrine and its interaction with G-proteins in adipocytes \[[@R10]\]. Since the year 1996, a growing number of epidemiological studies have tested the association of *ADRB3* gene Trp64Arg polymorphism with hypertension risk and the changes of relevant intermediate phenotypes, such as blood pressure, body mass index (BMI) and fasting insulin \[[@R4], [@R11]--[@R14]\]. However, the results of these studies are not satisfactory, as positive association cannot be reproduced coherently. As a meta-analysis is widely recognized as a useful and reliable method to address this issue, we set out to meta-analyze the association of *ADRB3* gene Trp64Arg polymorphism with both hypertension risk and blood pressure changes using existing publications.

RESULTS {#s2}
=======

Qualified studies {#s2_1}
-----------------

Using the prescribed keywords, a total of 201 publications in the English language were identified from searching three publicly-available databases. Among them, only 23 publications met preset inclusive criteria \[[@R4], [@R10]--[@R31]\]. The selection process of qualified publications is illustrated in Figure [1](#F1){ref-type="fig"}. There were 16 publications testing the association of *ADRB3* gene Trp64Arg polymorphism with hypertension risk \[[@R10], [@R11], [@R14], [@R16], [@R17], [@R19], [@R20], [@R23]--[@R31]\], incorporating 21 individual studies (3750 hypertensive patients and 4225 normotensive controls). Fourteen publications were available for the association of Trp64Arg polymorphism with blood pressure changes \[[@R4], [@R10], [@R12]--[@R15], [@R17], [@R18], [@R21]--[@R23], [@R25], [@R26], [@R28]\], incorporating 17 individual studies (6100 subjects). The baseline characteristics of all qualified studies are present in both [Supplementary Table 1](#SD2){ref-type="supplementary-material"} and Table [1](#T1){ref-type="table"}.

![The selection process of qualified publications for this meta-analysis](oncotarget-08-46480-g001){#F1}

###### The baseline characteristics of observational studies for the changes of blood pressure and related intermediate phenotypes

  First author      Year   Ethnicity   Design          BP cutoff   Source       Matched   Genotyping   Sample size   Age (years)   Males                                 
  ----------------- ------ ----------- --------------- ----------- ------------ --------- ------------ ------------- ------------- ------- ------ ------- ------- ------ ------
  Ikegami           1996   Japanese    Retrospective   140/90      Hospital     n.a.      RFLP         126           97            n.a.    n.a.   n.a.    n.a.           
  Fujisawa          1997   Japanese    Retrospective   160/95      Hospital     NO        RFLP         101           73            57.7    46.2   0.475   0.712          
  Baba              1998   Japanese    Retrospective   140/90      Hospital     YES       RFLP         37            46            57.0    55.0   0.568   0.565          
  Tonolo            1999   Caucasian   Retrospective   160/95      Hospital     YES       RFLP         213           281           62.0    61.0   0.460   0.374          
  Ringel (Men)      2000   Caucasian   Retrospective   n.a.        Hospital     NO        RFLP         86            122           61.6    57.8   1.000   1.000          
  Ringel (Women)    2000   Caucasian   Retrospective   n.a.        Hospital     NO        RFLP         115           94            64.4    59.8   0.000   0.000          
  Filigheddu        2004   Caucasian   Retrospective   140/90      Hospital     NO        RFLP         526           192           48.2    66.0   0.580   0.469          
  Masuo             2005   Japanese    Nested          140/90      Population   n.a.      TaqMan       41            117           n.a.    n.a.   n.a.    n.a.           
  Nagano            2005   Japanese    Retrospective   140/90      Hospital     n.a.      RFLP         23            66            n.a.    n.a.   0.551   0.551          
  Kawaguchi         2006   Japanese    Nested          140/90      Population   n.a.      TaqMan       27            28            n.a.    n.a.   n.a.    n.a.           
  Hui (Men)         2007   Chinese     Retrospective   160/100     Hospital     YES       TaqMan       170           182           51.0    52.0   1.000   1.000          
  Hui (Women)       2007   Chinese     Retrospective   160/100     Hospital     YES       TaqMan       91            89            51.1    50.4   0.000   0.000          
  Mo (Obese)        2007   Chinese     Retrospective   140/90      Hospital     YES       RFLP         149           149           57.4    57.8   0.597   0.456          
  Mo (Non-obese)    2007   Chinese     Retrospective   140/90      Hospital     YES       RFLP         139           149           58.1    57.8   0.576   0.456          
  Ruixing (Men)     2008   Chinese     Retrospective   140/90      Population   NO        RFLP         287           547           51.2    43.4   1.000   1.000          
  Ruixing (Women)   2008   Chinese     Retrospective   140/90      Population   NO        RFLP         159           676           55.2    43.8   0.000   0.000          
  Mirrakhimov       2011   Kyrgyz      Retrospective   n.a.        Population   n.a.      RFLP         87            126           50.7    50.7   0.681   0.681          
  Chou (Normal)     2012   Chinese     Nested          130/85      Population   n.a.      TaqMan       22            242           n.a.    n.a.   n.a.    n.a.           
  Chou (Obesity)    2012   Chinese     Nested          130/85      Population   n.a.      TaqMan       110           129           n.a.    n.a.   n.a.    n.a.           
  Wang              2014   Chinese     Retrospective   140/90      Hospital     YES       TaqMan       1090          700           51.9    51.8   0.606   0.597          
  Grygiel-Gorniak   2015   Caucasian   Retrospective   140/90      Population   NO        TaqMan       151           120           59.9    58.6   0.000   0.000          
  n.a.              n.a.   n.a.        n.a.            n.a.        n.a.         n.a.      n.a.         n.a.          n.a.          n.a.    n.a.   n.a.    n.a.    n.a.   n.a.
  24.1              22.2   155         122             92          76           n.a.      n.a.         n.a.          n.a.          5.27    5.25   n.a.    n.a.    n.a.   n.a.
  23.2              22.6   n.a.        n.a.            n.a.        n.a.         n.a.      n.a.         n.a.          n.a.          n.a.    n.a.   n.a.    n.a.    n.a.   n.a.
  30.1              26.7   n.a.        n.a.            n.a.        n.a.         n.a.      n.a.         1.49          1.48          5.90    5.80   1.40    1.50    3.70   3.60
  27.4              27.2   n.a.        n.a.            n.a.        n.a.         n.a.      n.a.         n.a.          n.a.          n.a.    n.a.   n.a.    n.a.    n.a.   n.a.
  29.0              27.3   n.a.        n.a.            n.a.        n.a.         n.a.      n.a.         n.a.          n.a.          n.a.    n.a.   n.a.    n.a.    n.a.   n.a.
  26.9              25.7   157         129             104         80           n.a.      n.a.         n.a.          n.a.          n.a.    n.a.   n.a.    n.a.    n.a.   n.a.
  n.a.              n.a.   n.a.        n.a.            n.a.        n.a.         n.a.      n.a.         n.a.          n.a.          n.a.    n.a.   n.a.    n.a.    n.a.   n.a.
  n.a.              n.a.   n.a.        n.a.            n.a.        n.a.         n.a.      n.a.         n.a.          n.a.          n.a.    n.a.   n.a.    n.a.    n.a.   n.a.
  n.a.              n.a.   n.a.        n.a.            n.a.        n.a.         n.a.      n.a.         n.a.          n.a.          n.a.    n.a.   n.a.    n.a.    n.a.   n.a.
  24.4              22.8   171.7       113.2           105.4       70.5         n.a.      n.a.         n.a.          n.a.          5.30    5.09   1.44    1.39    n.a.   n.a.
  24.4              22.5   177.1       112.1           70.5        68.2         n.a.      n.a.         n.a.          n.a.          5.70    5.45   1.64    1.58    n.a.   n.a.
  27.3              20.2   141.9       108.5           83.4        72.1         5.30      5.28         1.87          1.22          n.a.    n.a.   1.09    1.16    3.19   2.98
  21.7              20.2   141.2       108.5           82.4        72.1         5.31      5.28         1.28          1.22          n.a.    n.a.   1.17    1.16    3.01   2.98
  22.2              20.9   146.4       119.3           89.8        75.3         n.a.      n.a.         n.a.          n.a.          n.a.    n.a.   n.a.    n.a.    n.a.   n.a.
  20.1              21.2   149.4       115.7           84.3        72.1         n.a.      n.a.         n.a.          n.a.          n.a.    n.a.   n.a.    n.a.    n.a.   n.a.
  n.a.              n.a.   n.a.        n.a.            n.a.        n.a.         n.a.      n.a.         n.a.          n.a.          n.a.    n.a.   n.a.    n.a.    n.a.   n.a.
  n.a.              n.a.   n.a.        n.a.            n.a.        n.a.         n.a.      n.a.         n.a.          n.a.          n.a.    n.a.   n.a.    n.a.    n.a.   n.a.
  n.a.              n.a.   n.a.        n.a.            n.a.        n.a.         n.a.      n.a.         n.a.          n.a.          n.a.    n.a.   n.a.    n.a.    n.a.   n.a.
  26.5              24.8   141.77      115.66          90.85       75.62        5.43      5.17         2.09          1.43          n.a.    n.a.   1.16    1.40    3.42   3.48
  29.9              28.9   157.29      121.02          96.37       77.42        5.46      5.24         1.40          1.23          6.09    5.83   1.66    1.65    3.78   3.61

Trp64Arg and hypertension risk: integral analyses {#s2_2}
-------------------------------------------------

In view of a low frequency of 64Arg/64Arg homozygote and to avoid a fluctuated estimate, the risk prediction of Trp64Arg polymorphism for hypertension was investigated separately under the allelic, heterozygote-genotypic and dominant models.

The mean frequency of 64Arg allele was 15.86% in patients and 14.18% in controls, with the statistical power to detect the difference of being 83.74%. Integral analyses of 21 individual studies revealed that the mutation of *ADRB3* gene Trp64Arg polymorphism was associated with the significantly increased risk of hypertension under three genetic models mentioned above, in company with moderate or marginally significant heterogeneity as gauged by the *I*^2^ statistic (Figure [2](#F2){ref-type="fig"}). For example, carriers of the 64Trp/64Arg heterozygote were 1.23-times more likely to develop hypertension when compared with those of the 64Trp/64Trp homozygote (OR = 1.23, 95% CI: 1.02 ∼ 1.46, *P* = 0.021), with moderate heterogeneity (*I*^2^ = 46.9%). In addition, the genotype distributions of *ADRB3* gene Trp64Arg polymorphism deviated from the Hardy-Weinberg equilibrium in 4 studies, exclusion of these 4 studies generated the very similar effect estimates, with slightly improved heterogeneity.

![Forest graphs for the integral association of *ADRB3* gene Trp64Arg polymorphism with hypertension risk under the allelic (the upper panel), heterozygote-genotypic (the middle panel) and dominant (the lower panel) models](oncotarget-08-46480-g002){#F2}

Regarding publication bias, the likelihood of significance was extremely low for the three genetic models mentioned above, as supported by the symmetrical Begg\'s funnel graphs (Figure [3A](#F3){ref-type="fig"}, [3C](#F3){ref-type="fig"}, [3E](#F3){ref-type="fig"}) and the no-missing-study-reported filled funnel graphs (Figure [3B](#F3){ref-type="fig"}, [3D](#F3){ref-type="fig"}, [3F](#F3){ref-type="fig"}), as well as by the nonsignificant Egger\'s regression tests for funnel asymmetry (*P* = 0.705, 0.731 and 0.999 for the allelic, heterozygote-genotypic and dominant models, respectively).

![Begg\'s and filled funnel graphs for the association of ADRB3 gene Trp64Arg polymorphism with hypertension risk under the allelic (**A** and **B** panels), heterozygote-genotypic (**C** and **D** panels) and dominant (**E** and **F** panels) models.](oncotarget-08-46480-g003){#F3}

Trp64Arg and hypertension risk: stratified analyses {#s2_3}
---------------------------------------------------

Because the heterogeneity in integral analyses was moderate or significant, a string of stratified analyses and meta-regression analyses were implemented to look for the possible reasons in explanation of between-study heterogeneity from other demographic and methodological aspects. In stratified analyses, 21 qualified studies were grouped per ethnicity, study design, source of control populations, genotyping methodology, age-matched condition, BMI in patients and total sample size respectively under the allelic, heterozygote-genotypic and dominant models (Table [2](#T2){ref-type="table"}).

###### The risk prediction of *ADRB3* gene Trp64Arg mutation for hypertension under three genetic models in stratified analyses

  Subgroups                           Allelic model       Heterozygote-genotypic model   Dominant model                                                                       
  ------------------------------ ---- ------------------- ------------------------------ ---------------- ------------------- --------- ------- ------------------- --------- -------
  ***Ethnicity***                                                                                                                                                             
  Caucasian                      5    1.49, 0.92 ∼ 2.41   0.103                          70.1%            1.54, 0.94 ∼ 2.52   0.085     65.9%   1.54, 0.93 ∼ 2.57   0.095     69.5%
  Chinese                        9    1.17, 1.04 ∼ 1.31   0.008                          0.0%             1.23, 1.07 ∼ 1.41   0.003     0.0%    1.22, 1.07 ∼ 1.39   0.003     0.0%
  Japanese                       6    0.82, 0.51 ∼ 1.31   0.400                          60.3%            0.79, 0.45 ∼ 1.37   0.402     58.7%   0.79, 0.45 ∼ 1.38   0.400     62.4%
  ***Study design***                                                                                                                                                          
  Nested                         4    1.08, 0.50 ∼ 2.35   0.842                          74.2%            0.97, 0.38 ∼ 2.43   0.943     75.8%   1.03, 0.41 ∼ 2.59   0.948     77.1%
  Retrospective                  17   1.22, 1.05 ∼ 1.42   0.011                          45.7%            1.28, 1.09 ∼ 1.50   0.002     31.6%   1.27, 1.08 ∼ 1.50   0.004     40.9%
  *Source of controls*                                                                                                                                                        
  Hospital                       13   1.22, 0.98 ∼ 1.50   0.072                          56.5%            1.27, 1.02 ∼ 1.57   0.030     42.0%   1.26, 1.01 ∼ 1.58   0.043     50.6%
  Population                     8    1.17, 0.91 ∼ 1.50   0.234                          49.8%            1.16, 0.84 ∼ 1.62   0.373     58.3%   1.18, 0.85 ∼ 1.63   0.316     59.2%
  ***Genotyping methodology***                                                                                                                                                
  RFLP                           13   1.25, 1.01 ∼ 1.54   0.037                          54.2%            1.27, 1.02 ∼ 1.59   0.034     44.4%   1.28, 1.02 ∼ 1.62   0.032     51.4%
  TaqMan                         8    1.11, 0.86 ∼ 1.43   0.416                          48.6%            1.15, 0.84 ∼ 1.58   0.382     55.8%   1.14, 0.84 ∼ 1.56   0.404     56.1%
  ***Age-matched condition***                                                                                                                                                 
  n.a.                           7    1.03, 0.68 ∼ 1.57   0.879                          64.1%            1.01, 0.60 ∼ 1.71   0.968     68.0%   1.03, 0.61 ∼ 1.74   0.914     69.5%
  NO                             7    1.22, 0.94 ∼ 1.58   0.130                          54.1%            1.25, 0.95 ∼ 1.65   0.115     46.3%   1.25, 0.94 ∼ 1.67   0.119     52.5%
  YES                            7    1.28, 1.01 ∼ 1.62   0.038                          45.7%            1.32, 1.10 ∼ 1.58   0.003     5.8%    1.33, 1.07 ∼ 1.64   0.011     25.5%
  ***Mean BMI in patients***                                                                                                                                                  
  BMI \< 25 kg/m^2^              7    1.19, 1.02 ∼ 1.39   0.029                          0.0%             1.24, 1.03 ∼ 1.49   0.025     0.0%    1.23, 1.03 ∼ 1.48   0.022     0.0%
  BMI ≥ 25 kg/m^2^               14   1.22, 0.96 ∼ 1.55   0.105                          63.6%            1.23, 1.03 ∼ 1.60   0.136     61.3%   1.24, 0.95 ∼ 1.63   0.118     64.4%
  ***Total sample size***                                                                                                                                                     
  \< 240                         11   1.06, 0.76 ∼ 1.48   0.725                          68.5%            1.07, 0.72 ∼ 1.57   0.746     67.4%   1.07, 0.72 ∼ 1.59   0.736     70.5%
  ≥ 240                          10   1.20, 1.07 ∼ 1.35   0.002                          0.0%             1.29, 1.13 ∼ 1.48   \<0.001   0.0%    1.27, 1.11 ∼ 1.44   \<0.001   0.0%

Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; RFLP, restriction fragment length polymorphism; BMI, body mass index; n.a., not available.

When all studies were grouped by ethnicity, significance was only revealed in populations of Chinese descent (*n* = 9) for the association of Trp64Arg polymorphism with hypertension risk under all three genetic models, and no evidence of heterogeneity occurred (*I*^2^ = 0.0% for all models). By study design, the risk prediction was only significant in retrospective studies (*n* = 17), with moderate heterogeneity. By source of controls, effect-size estimates were potentiated in hospital-based studies (*n* = 13) relative to population-based studies (*n* = 8), especially under the heterozygote-genotypic and dominant models, and there was moderate evidence of heterogeneity. By genotyping methodology, studies using RFLP (restriction fragment length polymorphism) technique reported a significant association of Trp64Arg mutation with hypertension under all three genetic models, and this association was biased by significant heterogeneity. By age-matched condition, the mutation of Trp64Arg polymorphism was significantly associated with the increased risk of hypertension in studies involving age-matched hypertensive patients and normotensive controls (*n* = 7), and the probability of heterogeneity was considerably improved under the heterozygote-genotypic (*I*^2^ = 5.8%) and dominant (*I*^2^ = 25.5%) models. By mean BMI in patients at a cutoff value of 25 kg/m^2^, the risk prediction of Trp64Arg polymorphism for hypertension was significant when analysis was restricted to the studies enrolling patients with mean BMI \< 25 kg/m^2^ (*n* = 7) under the allelic (OR=1.19, 95% CI: 1.02 ∼ 1.39, *P* = 0.029), heterozygote-genotypic (OR=1.24, 95% CI: 1.03 ∼ 1.49, *P* = 0.025) and dominant (OR=1.23, 95% CI: 1.03 ∼ 1.48, *P* = 0.022), without heterogeneity (all *I*^2^ = 0.0%). Finally, grouping studies by total sample size at the medium cutoff value of 240 found a robust association in larger studies (*n* = 10) between Trp64Arg polymorphism and hypertension risk under the allelic (OR=1.20, 95% CI: 1.07 ∼ 1.35, *P* = 0.001), heterozygote-genotypic (OR=1.29, 95% CI: 1.13 ∼ 1.48, *P* \< 0.001) and dominant (OR=1.27, 95% CI: 1.11 ∼ 1.44, *P* \< 0.001) models, respectively, and there was no detectable heterogeneity (all *I*^2^ = 0.0%).

Further meta-regression analyses, when modeling the baseline (age, gender, BMI, smoking) and clinical (FBG, triglycerides, total cholesterol, HDLC, LDLC) characteristics, failed to detect any significant contributions on the risk prediction of Trp64Arg polymorphism for hypertension under all three genetic models (all *P* \> 0.05) (data not shown).

Trp64Arg and intermediate phenotype changes {#s2_4}
-------------------------------------------

Because of the close relation of β3-adrenoreceptor with obesity and lipolysis, besides blood pressure, the levels of other related intermediate phenotypes including BMI, FBG, fasting insulin, total cholesterol and HDLC were also compared across Trp64Arg genotypes. Considering a low frequency of the 64Arg/64Arg homozygote, the 64Trp/64Arg heterozygote is often combined with the 64Arg/64Arg homozygote when assessing the changes of these phenotypes across these genotypes. To avoid deviations from inadequate sample sizes, blood pressure and related intermediate phenotypes were only compared between carriers of the 64Trp/64Trp and 64Trp/64Arg genotypes (Table [3](#T3){ref-type="table"}). Integral analyses of 17 individual studies failed to detect any significant changes in blood pressure and related intermediate phenotypes between the 64Trp/64Trp and 64Trp/64Arg genotypes. Further grouping 17 studies by hypertension status found that in hypertensive patients, the 64Trp/64Arg heterozygote carriers had significantly higher SBP (WMD=0.87 mmHg, 95% CI: 0.39 ∼ 1.35, *P* \< 0.001) and DBP (WMD=0.88 mmHg, 95% CI: 0.59 ∼ 1.17, *P \<* 0.001) levels than those with the 64Trp/64Trp homozygote, with no detectable heterogeneity (both *I*^2^ = 0.0%). By contrast, BMI was 3.00 kg/m^2^ higher in normotensive controls possessing the 64Trp/64Arg heterozygote than the 64Trp/64Trp homozygote (WMD=3.00, 95% CI: 0.35 ∼ 5.66, *P* = 0.026), without heterogeneity (*I*^2^ = 0.0%), while it was 0.70 kg/m^2^ lower in hypertensive patients. As for total cholesterol, normotensive controls with the 64Trp/64Arg heterozygote had a lower level than those with the 64Trp/64Trp homozygote (WMD=−0.39 mmol/L, 95% CI: −0.73 ∼ −0.05, *P* = 0.026), without heterogeneity (*I*^2^ = 0.0%). No significant changes were observed in FBG, fasting insulin and HDLC levels across Trp64Arg genotypes (all *P* \> 0.05).

###### Pooled changes of blood pressure and related intermediate phenotypes between carriers of the 64Trp/64Trp and 64Trp/64Arg genotypes

  Phenotypes                   Groups        Studies (N)   WMD             95% CI         *P*     *I^2^*
  ---------------------------- ------------- ------------- --------------- -------------- ------- --------
  SBP (mmHg)                   All studies   16            1.67            −0.48 ∼ 3.82   0.128   80.7%
  Studies in hypertensives     6             0.87          0.39 ∼ 1.35     \< 0.001       0.0%    
  DBP (mmHg)                   All studies   16            0.29            −0.28 ∼ 0.87   0.317   15.3%
  Studies in hypertensives     6             0.88          0.59 ∼ 1.17     \< 0.001       0.0%    
  BMI (kg/m^2^)                All studies   14            −0.06           −0.59 ∼ 0.48   0.838   83.4%
  Studies in hypertensives     5             −0.70         −1.24 ∼ -0.17   0.010          42.1%   
  FBG (mmol/L)                 All studies   6             0.01            −0.06 ∼ 0.07   0.835   0.0%
  Studies in hypertensives     3             0.03          −0.08 ∼ 0.15    0.574          12.0%   
  Fasting insulin (pmol/L)     All studies   11            −0.94           −7.00 ∼ 5.12   0.762   71.1%
  Studies in hypertensives     3             −2.07         −11.54 ∼ 7.39   0.668          0.0%    
  Total cholesterol (mmol/L)   All studies   12            −0.03           −0.12 ∼ 0.05   0.433   49.9%
  Studies in hypertensives     4             0.00          −0.04 ∼ 0.04    0.891          2.8%    
  HDLC (mmol/L)                All studies   9             −0.01           −0.06 ∼ 0.03   0.580   64.9%
  Studies in hypertensives     4             −0.01         −0.08 ∼ 0.07    0.879          50.7%   

Abbreviations: WMD, weighted mean difference; 95% CI, 95% confidence interval; SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; FBG, fasting blood glucose; HDLC, high-density lipoprotein cholesterol.

DISCUSSION {#s3}
==========

To the best of our knowledge, this is to date the first meta-analysis to test the association of *ADRB3* gene Trp64Arg polymorphism with both hypertension risk and blood pressure changes. Most notably, the mutation of Trp64Arg polymorphism was significantly associated not only with an increased predisposition toward hypertension, but also with elevated SBP and DBP in hypertensive patients, suggesting that Trp64Arg polymorphism might represent an important genetic marker in the development of hypertension.

Human β3-adrenoreceptor is a member of the family of 7-transmembrance G-protein-coupled receptors. It is widely recognized that the β3-adrenoreceptor is indirectly involved in the etiology of hypertension through reducing lipolysis and activating the sympathetic nervous system \[[@R25], [@R32]\]. Numerous studies have suggested that hypertension is partly under genetic control, and therefore to look for candidate genetic markers responsible for hypertension predisposition and/or blood pressure changes is justifiable \[[@R33], [@R34]\]. Given the biological importance of β3-adrenoreceptor, it would be tempting to speculate that certain genetic alterations of its coding gene, *ADRB3*, might play a critical role in the regulation of blood pressure and ultimately predispose to the occurrence of hypertension.

The genomic sequence of *ADRB3* gene is covered with many polymorphic loci, and a missense mutation, Trp64Arg, in its first exon has been widely evaluated in susceptibility to hypertension and other complications in populations from different regions of the world \[[@R20], [@R24], [@R35]\]. Some studies have reported the increased risk of hypertension associated with the 64Arg allele \[[@R10], [@R17], [@R26]\], whereas others have found an apparently conflicting association \[[@R25], [@R31]\]. This controversy could be attributed to the differences in genetic background, study design, source of study subjects, sample size and so on \[[@R36]\]. So, attempts to account for these differences have justified the necessity of undertaking a systematic meta-analysis, just as the present study did.

Our integral analyses demonstrated that the mutation of Trp64Arg polymorphism was associated with the significantly increased risk of hypertension, and this association was further substantiated in age-matched case-control studies and in larger studies, irrespective of three genetic models under investigation, highlighting the robustness of our meta-analytical findings. However, in many cases, complex diseases like hypertension are complicated by genetic heterogeneity \[[@R37]\]. As demonstrated by our ethnicity-stratified analyses, there was no exception for *ADRB3* gene Trp64Arg polymorphism either. The risk prediction of this polymorphism for hypertension was spotted in populations of Chinese descent, whereas the Trp64Arg mutation seemed to act as a protective factor against the occurrence of hypertension in Japanese, albeit nonsignificantly. The possible reasons for such divergence could be due to differences in statistical power, genetic background, environmental exposure or dietary habit. Hence, the presence of genetic heterogeneity might undermine the replication of association between *ADRB3* gene and hypertension. In addition, our findings also suggested that the differences in study design, genotyping methodology, age-matched condition, obesity and total sample size might be the potential sources of between-study heterogeneity. Altogether, our findings not only confirmed the susceptible role of *ADRB3* gene Trp64Arg polymorphism in the development of hypertension, but also aid in explaining the conflicting patterns of the association seen in prior studies.

Another important finding of this meta-analysis was the significant changes in blood pressure across *ADRB3* gene Trp64Arg genotypes. In fact, the heterozygous carriers of Trp64Arg polymorphism were found to have significantly higher SBP and DBP than those with the 64Trp/64Trp genotype in hypertensive patients, which can serve as an apt explanation for the risk-conferring association of the 64Arg allele with hypertension, as discussed above. It is generally believed that the sympathetic nervous system represents a major regulator of blood pressure through alterations in sodium homeostasis and vascular resistance \[[@R38], [@R39]\]. So, we speculate that the mutation of Trp64Arg polymorphism might impact on the function of β3-adrenoreceptor, which can further activate sympathetic nervous system, regulate blood pressure and ultimately precipitate the development of hypertension.

Study limitations {#s3_1}
-----------------

This meta-analysis is based on observational data from genetic association studies, and the potential causality cannot be handled. Moreover, only the English publications were meta-analyzed, and doing so might raise a possible selection bias. However, as manifested by the Begg\'s funnel graph, the filled funnel graph and the Egger\'s regression asymmetry test, publication bias was unlikely to be a perplexing issue. In addition, only one missense mutation was analyzed in the present study, and it is highly encouraged to incorporate more polymorphisms in close linkage disequilibrium with Trp64Arg polymorphism in *ADRB3* gene and other adrenoreceptor genes, such as *ADRB1* and *ADRB2* genes, pending sufficient available publications to investigate their joint impact on blood pressure and hypertension risk. Also, because β3-adrenoreceptor is a principal component of adipose tissue, we only stratified the studies according to mean BMI, an indication of general obesity, and did not assess another important index of abdominal obesity, waist-to-hip ratio due to insufficient eligible studies. Furthermore, this meta-analysis was limited by inadequate sample size, especially in some subgroups. We concede that replication of our findings in other well-designed studies with a larger sample size will add additional evidence to our existing knowledge on a contributing role of *ADRB3* gene to the etiology of hypertension.

MATERIALS AND METHODS {#s4}
=====================

Search information {#s4_1}
------------------

To be as comprehensive as possible, a systematic search of three publicly-available electronic databases, Medline, Embase (Excerpta Medica Database) and Web of Science, was launched to look for articles published as of December 14, 2016. The prescribed MeSH key terms incorporated "β3-adrenoreceptor" or "β3-adrenergic receptor" or "beta3-adrenoreceptor" or "beta3-adrenergic receptor" or "β3-adrenoreceptor" or "ADRB3" or "3-BAR" or "beta3-AR" in the Title/Abstract, annexed with "hypertension" or "hypertensive" or "blood pressure" in the Title and "genetic" or "polymorphism" or "SNP" or "variant" or "mutation" or "genotype" or "allele" in the Title/Abstract. Search results were primarily confined to the English-only articles involving human beings, irrespective of races or ethnicities or study designs. Search scope was further expanded to include reference lists of the keywords-indexed results to avoid possible omissions. Search process was done by two researchers - Hualing Yang and Dongmiao Cai, and the final publication list was based on congregated results of two researchers by removing duplications with the EndNote citation manager software version X8 (Thomson Reuters).

Inclusive criteria {#s4_2}
------------------

Inclusive criteria were determined by all listed authors of this study, from the following three respects: (i) study design: either retrospective or nested; (ii) genetic data: the genotype or allele distributions of *ADRB3* gene Trp64Arg polymorphism between hypertensive patients and normotensive controls or the mean and standard deviation of systolic blood pressure (SBP) and diastolic blood pressure (DBP) in mmHg, and when available other related intermediate phenotypes, including BMI, fasting blood glucose (FBG), fasting insulin, total cholesterol and HDLC across Trp64Arg genotypes; (iii) the genotypes of Trp64Arg polymorphism distinguished by validated methods. Two researchers - Hualing Yang and Dongmiao Cai, independently filtrated eligible articles from all keywords- and references-indexed search results per the inclusive criteria formulated above, and they also fixed all discrepancies with consensus.

Data extraction {#s4_3}
---------------

A data-extraction table in Excel version 2016 was delineated by all listed authors, and extraction process was implemented by the same two researchers - Hualing Yang and Dongmiao Cai. The extracted data of interest contained the first author\'s family name, year of publication, country of samples collected, race or ethnicity of study subjects, study design, source of control populations, age-matched condition between patients and controls, genotyping methodology, sample size, age, gender, BMI, smoking, SBP, DBP, FBG, triglycerides, total cholesterol, high-density lipoprotein cholesterol (HDLC), low-density lipoprotein cholesterol, the genotype or allele distributions of Trp64Arg polymorphism between patients and controls, and the mean and standard deviation of SBP, DBP, BMI, FBG, fasting insulin, total cholesterol and HDLC levels across Trp64Arg genotypes, where existing. Two independently-extracted tables were compared for divergence, and any disagreement was resolved through discussion.

Statistical analyses {#s4_4}
--------------------

The risk prediction of *ADRB3* gene Trp64Arg polymorphism for hypertension was signified as odds ratio (OR) and its 95% confidence interval (95% CI), and the changes of blood pressure and other related intermediate phenotypes were signified as weighted mean difference (WMD) and its 95% CI. Individual effect-size estimates were combined under random-effects model adopting the method developed by DerSimonian R and Laird N \[[@R40]\]. Statistical heterogeneity of individual studies was expressed as the *I*^2^ statistic, a per cent number that can be interpreted as low (*I*^2^ ≤ 25%), moderate (*I*^2^ \> 25% and *I*^2^ \< 50%) or high (*I*^2^ ≥ 50%) \[[@R41]\]. Other sources of heterogeneity from demographic and methodological aspects were probed by stratified analyses and meta-regression analyses. Publication bias was gauged by the Begg\'s funnel graph, the filled funnel graph and the Egger\'s regression asymmetry test \[[@R42]\]. The probability for the Egger\'s test was significant at 10% or less. In the presence of missing studies, an unbiased estimate was derived by the trim-and-fill method. Data were statistically analyzed by the Meta-analysis module \[[@R43]\] in the Stata/SE software version 14.1 for the Windows. Study power was estimated by the "sampsi" order in the Stata/SE software.

CONCLUSIONS {#s5}
===========

The collective findings of this meta-analysis demonstrated that the mutation of Trp64Arg polymorphism was significantly associated not only with an increased predisposition toward hypertension, but also with elevated SBP and DBP in hypertensive patients, suggesting that Trp64Arg polymorphism might represent an important genetic marker in the development of hypertension. These findings will potentially further our understanding for the contributing role of *ADRB3* gene Trp64Arg polymorphism in blood pressure regulation and in the pathogenesis of hypertension.

SUPPLEMENTARY MATERIALS FIGURES AND TABLES {#s6}
==========================================
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